PRAGMA Therapeutics is a French leading neuroscience biotech company discovering and developing proprietary small molecule therapeutics for the treatment of stress-related diseases, in particular Post-Traumatic Stress Disorders (PTSD), and hearing loss.
Founded in 2015, PRAGMA is a flexible organization led by a team with a world-leading experience in neuroscience drug development, targeting  a specific class of G-protein-coupled receptors (GPCR), the metabotropic glutamate receptors family (mGluRs).

PRAGMA currently develops allosteric modulators of the mGlu7 subtype which corresponds to a unique and innovative approach to regulate stress-related responses, fear and cognitive dysfunctions associated to PTSD, as well as acute and acoustic trauma-induced hearing loss.

PRAGMA has integrated the new standards of drug development and aims at rapidly correlating in vivo proof-of-concept studies with target engagement and pharmacodynamic biomarkers in human in order to increase its success rate in clinical trials.